Aurora Spine Corporation (ASG) Fair Value & Analysis
Healthcare · CA · Market cap C$17.6M
Fair value as of: Jun 24, 2026
From 11 valuation models · updated 8 days ago
Fair value updated Jun 24, 2026 — revised from C$0.1500 to C$0.1100 (−26.7%) since Jun 23, 2026. Share price +6.3% over the past month.
Price vs Fair Value (12 months)
12‑month range C$0.1849 – C$0.3157 · fair‑value band C$0.0700 – C$0.1400 · the C$0.2300 price screens above the C$0.1100 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Aurora Spine Corporation (ASG) currently trades at C$0.2300, while our model-based Fair Value estimate is C$0.1100 — implying the stock looks roughly 52.2% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Aurora Spine Corporation generated revenue of C$18.4M at a net margin of -3.2%. Revenue grew 0.4% year over year. It earns a return on equity of -15.1%. Net debt stands at C$2.0M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTR, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases. It also provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone lumbar fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior allograft implant; and SiLO TFX, a titanium implant device for sacroiliac joint fusion. In addition, the company offers Dexa-C, a 3D printed cervical fusion device, which is a porous 3D-printed intervertebral cage that incorporates lattice pattern options to support the matching of patients' bone quality, as well as DEXA SOLO-L, a spinal device implanted in the …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aurora Spine Corporation reported revenue of C$18.4M in FY2025 versus C$10.5M in FY2021, a compound +14.9%/yr. Reported net income was −C$731K in FY2025.
Is ASG fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ABT ABT | 1,600 MXN | 1,228 MXN | -23% |
| Abbott Laboratories, ABTT34 | R$38.22 | R$30.39 | -20% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aurora Spine Corporation (ASG) undervalued?
What is the fair value of ASG?
What is the quality score of ASG?
What is the revenue of Aurora Spine Corporation (ASG)?
What is the net profit margin of ASG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.